Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fadi Braiteh

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
JAMA Oncology|February 10, 2018
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 StudyDaniel P Petrylak, Thomas Powles, Joaquim Bellmunt, et al.
Oncotarget|May 17, 2018
Signature program: a platform of basket trialsEric D Slosberg, Barinder P Kang, Julio Peguero, et al.
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Gynecologic Oncology|June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancersJoyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Clinical Lung Cancer|November 19, 2016
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung CancerHeather Wakelee, Zanete Zvirbule, Filippo De Braud, et al.
International Journal of Cancer|January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumorsIgnacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Investigational New Drugs|September 28, 2014
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumorsRobert M Jotte, Daniel D Von Hoff, Fadi Braiteh, et al.
The Oncologist|October 12, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
JAMA Oncology|February 10, 2018
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 StudyDaniel P Petrylak, Thomas Powles, Joaquim Bellmunt, et al.
Oncotarget|May 17, 2018
Signature program: a platform of basket trialsEric D Slosberg, Barinder P Kang, Julio Peguero, et al.
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Gynecologic Oncology|June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancersJoyce F Liu, Michael Gordon, Jennifer Veneris, et al.
Clinical Lung Cancer|November 19, 2016
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung CancerHeather Wakelee, Zanete Zvirbule, Filippo De Braud, et al.
International Journal of Cancer|January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumorsIgnacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Investigational New Drugs|September 28, 2014
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumorsRobert M Jotte, Daniel D Von Hoff, Fadi Braiteh, et al.
The Oncologist|October 12, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
The Oncologist|March 10, 2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal CancerRocío García-Carbonero, Eric van Cutsem, Fernando Rivera, et al.
Pageof 7